GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Incannex Healthcare Inc (NAS:IXHL) » Definitions » Profitability Rank

Incannex Healthcare (Incannex Healthcare) Profitability Rank : 0 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Incannex Healthcare Profitability Rank?

Incannex Healthcare has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Incannex Healthcare's Operating Margin % for the quarter that ended in Dec. 2023 was %. As of today, Incannex Healthcare's Piotroski F-Score is 2.


Competitive Comparison of Incannex Healthcare's Profitability Rank

For the Drug Manufacturers - Specialty & Generic subindustry, Incannex Healthcare's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incannex Healthcare's Profitability Rank Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Incannex Healthcare's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Incannex Healthcare's Profitability Rank falls into.



Incannex Healthcare Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Incannex Healthcare has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Incannex Healthcare's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-5.256 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Incannex Healthcare has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Incannex Healthcare Profitability Rank Related Terms

Thank you for viewing the detailed overview of Incannex Healthcare's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Incannex Healthcare (Incannex Healthcare) Business Description

Traded in Other Exchanges
N/A
Address
8 Century Circuit Norwest, Suite 105, Sydney, NSW, AUS, 3000
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products.